A Phase II Trial of High Dose Interleukin-2 and Multi-site Stereotactic Ablative Radiotherapy for Patients with Metastatic Renal Cell Carcinoma
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ega/EGAS00001003605
下载链接
链接失效反馈官方服务：
资源简介：
Immune-based therapies have improved outcomes for metastatic renal cell carcinoma (mRCC) but there is still a significant margin for improvement. Here, we report the results of a phase II trial combining high dose Interleukin-2 (HD-IL-2) with stereotactic ablative body radiotherapy (SAbR) for patients with metastatic renal cell carcinoma.EGA study EGAS00001003605
创建时间：
2020-02-04
